ERNA
Ernexa Therapeutics Inc. NASDAQ Listed Aug 29, 1991$7.82
Mkt Cap $2.5M
52w Low $3.18
4.7% of range
52w High $101.25
50d MA $5.80
200d MA $25.65
P/E (TTM)
-0.1x
EV/EBITDA
-0.7x
P/B
0.4x
Debt/Equity
0.2x
ROE
-586.6%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
6.85
50d MA
$5.80
200d MA
$25.65
Avg Volume
1.8M
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
10355 Science Center Drive · Cambridge, MA 92121 · US
Data updated apr 25, 2026 7:35am
· Source: massive.com